Φορτώνει......
The role of stereotactic body radiation therapy in oligometastatic colorectal cancer: Clinical case report of a long-responder patient treated with regorafenib beyond progression
RATIONALE: Regorafenib is the new standard third-line therapy in metastatic colorectal cancer (mCRC). However, the reported 1-year overall survival rate does not exceed 25%. PATIENT CONCERNS: A 55-year-old man affected by mCRC, treated with regorafenib combined with stereotactic body radiotherapy (S...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Medicine (Baltimore) |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Wolters Kluwer Health
2017
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5728821/ https://ncbi.nlm.nih.gov/pubmed/29310420 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000009023 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|